Literature DB >> 35673506

Role of metabolizing MTHFR gene polymorphism (rs1801133) and its mRNA expression among Type 2 Diabetes.

Divya Pathak1, Dharmsheel Shrivastav2, Amit K Verma3, Abdulrahman A Alsayegh4, Prasant Yadav5, Nawaid Hussain Khan6, Alhanouf I Al-Harbi7, Mohammad Idreesh Khan8, Kapil Bihade9, Desh Deepak Singh2, Mirza Masroor Ali Beg6,10.   

Abstract

Objective: Type 2 Diabetes is a glucose metabolic disorder occurred by insulin insensitivity in which folate metabolism plays an important role. it is believed that polymorphism of Methylenetetrahydrofolate reductase (MTHFR) C677T linked with type 2 diabetes mellitus. However, results are conflicted. therefore, in this study we re-examine the relationship between MTHFR C677T in type 2 diabetes mellitus patients.
Methods: Present research work included 100 newly diagnosed type 2 diabetic mellitus (T2DM) cases and 100 healthy individuals. After the blood sample collection all the biochemical parameters were evaluated among the T2DM cases and healthy individuals. DNA and RNA extraction from whole blood was done to study the MTHFR gene polymorphism by allele specific polymerase chain reaction method and its expression analysis was done by quantitative real time polymerase chain reaction method.
Results: The significant difference was observed in genotype distribution among case and control group (p=0.0002). Compared with wildtype CC genotype, CT heterozygous (OR=2.95, 95% Cl=1.62-5.38) and TT homozygous (OR=3.20, CI=1.79-5.73) suggest to have effect of MTHFR polymorphism on type 2 mellitus risk. Moreover, relative MTHFR mRNA expression was found for wild type CC genotype 3.02-fold, CT heterozygous genotype 2.57 fold and mutant TT homozygous genotype 0.50-fold which is down regulated (p<0.0001).
Conclusion: Our results indicates that the polymorphism in MTHFR C677T plays significant role in type II diabetes risk. MTHFR CT heterozygous and mutant TT genotype showed reduced mRNA expression among the T2DM patients. However, large scale case-control studies are needed to strengthen such conclusion in the future. © Springer Nature Switzerland AG 2022.

Entities:  

Keywords:  Diabetes mellitus; Methylenetetrahydrofolate reductase; Polymorphism; Quantification RT-PCR

Year:  2022        PMID: 35673506      PMCID: PMC9167251          DOI: 10.1007/s40200-022-01001-7

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  26 in total

Review 1.  β-Cell Fate in Human Insulin Resistance and Type 2 Diabetes: A Perspective on Islet Plasticity.

Authors:  Teresa Mezza; Francesca Cinti; Chiara Maria Assunta Cefalo; Alfredo Pontecorvi; Rohit N Kulkarni; Andrea Giaccari
Journal:  Diabetes       Date:  2019-06       Impact factor: 9.461

Review 2.  Methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and diabetic nephropathy susceptibility in patients with type 2 diabetes mellitus.

Authors:  Tian-Biao Zhou; Gregor P C Drummen; Zong-Pei Jiang; Hong-Yan Li
Journal:  Ren Fail       Date:  2015-07-10       Impact factor: 2.606

Review 3.  Dyslipidemia in type 2 diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-03

4.  Expression and clinical significance of methylenetetrahydrofolate reductase in patients with colorectal cancer.

Authors:  Elisabeth Odin; Yvonne Wettergren; Göran Carlsson; Peter V Danenberg; Angelo Termini; Roger Willén; Bengt Gustavsson
Journal:  Clin Colorectal Cancer       Date:  2006-01       Impact factor: 4.481

5.  Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients.

Authors:  Jiazhong Sun; Yancheng Xu; Yilian Zhu; Hongyun Lu
Journal:  Diabetes Res Clin Pract       Date:  2004-06       Impact factor: 5.602

6.  Globalization of diabetes: the role of diet, lifestyle, and genes.

Authors:  Frank B Hu
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

Review 7.  Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.

Authors:  Yanling Wu; Yanping Ding; Yoshimasa Tanaka; Wen Zhang
Journal:  Int J Med Sci       Date:  2014-09-06       Impact factor: 3.738

8.  Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Subacute Combined Degeneration: Revealing a Genetic Predisposition.

Authors:  Xin Zhang; Chen Hou; Peng Liu; Li Chen; Yue Liu; Peng Tang; Rui Li
Journal:  Front Neurol       Date:  2019-01-09       Impact factor: 4.003

9.  Association of MTHFR C677T polymorphism and type 2 diabetes mellitus (T2DM) susceptibility.

Authors:  Yanzi Meng; Xiaoling Liu; Kai Ma; Lili Zhang; Mao Lu; Minsu Zhao; Min-Xin Guan; Guijun Qin
Journal:  Mol Genet Genomic Med       Date:  2019-10-30       Impact factor: 2.183

10.  MTHFR (methylenetetrahydrofolate reductase: EC 1.5.1.20) SNPs (single-nucleotide polymorphisms) and homocysteine in patients referred for investigation of fertility.

Authors:  Yves Ménézo; Pasquale Patrizio; Silvia Alvarez; Edouard Amar; Michel Brack; Charles Brami; Jacques Chouteau; Arthur Clement; Patrice Clement; Marc Cohen; Dominique Cornet; Brian Dale; Guiseppe D' Amato; Laetitia Jacquesson-Fournols; Pierre Mares; Paul Neveux; Jean Clement Sage; Edouard Servy; To Minh Huong; Geraldine Viot
Journal:  J Assist Reprod Genet       Date:  2021-04-29       Impact factor: 3.412

View more
  1 in total

Review 1.  A review on contemporary nanomaterial-based therapeutics for the treatment of diabetic foot ulcers (DFUs) with special reference to the Indian scenario.

Authors:  Lakshimipriya Sethuram; John Thomas; Amitava Mukherjee; Natarajan Chandrasekaran
Journal:  Nanoscale Adv       Date:  2022-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.